Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, and its news flow reflects both internal pipeline progress and partner-driven milestones. The company regularly issues updates on its XmAb® drug candidates, including T-cell engaging bispecific antibodies and Fc-engineered antibodies that use its XmAb and Xtend™ technologies.
Investors following XNCR news can expect detailed announcements on clinical trial progress across oncology and autoimmune indications. Recent releases have covered Phase 1 and Phase 2 studies of programs such as XmAb819 for advanced clear cell renal cell carcinoma, XmAb541 for gynecologic and germ cell tumors, plamotamab for rheumatoid arthritis, XmAb657 for idiopathic inflammatory myopathies, and XmAb942 and XmAb412 for inflammatory bowel and other autoimmune diseases. These updates often include safety and efficacy summaries, dose-escalation status, and plans for pivotal or proof-of-concept studies.
Xencor’s news stream also features financial results and guidance, including quarterly earnings, cash and marketable securities levels, and commentary on how its balance sheet supports research and development plans. In addition, the company reports on intellectual property developments, such as U.S. patent issuances that extend royalty terms on Xtend-based antibodies like Ultomiris, and on collaboration milestones with partners including Amgen, Astellas, Incyte and Zenas Biopharma.
Corporate governance and strategic updates, such as board appointments and participation in investor conferences, are also common topics. For investors and analysts, the XNCR news page provides a centralized view of how Xencor’s XmAb technology platform is progressing in the clinic, how partnered programs are advancing, and how these activities translate into milestones, royalties and long-term development plans.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced the appointment of Nancy Valente, M.D., as Executive Vice President and Chief Development Officer, effective May 1, 2023. Dr. Valente brings over 20 years of experience in biopharmaceutical product development, previously serving as a senior vice president at Genentech. She has been an independent board member since September 2022 and will now lead Xencor's clinical and medical strategy. Allen Yang, M.D., Ph.D., Chief Medical Officer, will assist during the transition before pursuing other opportunities. Dr. Valente's expertise will support Xencor's efforts to develop its clinical pipeline and deliver effective therapeutics for cancer and autoimmune diseases.
Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company focused on engineered antibodies for cancer treatment, presented preclinical data on CD28 bispecific antibodies targeting solid tumor antigens at the AACR Annual Meeting in Orlando, Florida. The study showcased enhanced T cell activation when combined with a CD3 T cell engager. Xencor's XmAb® platform enables rapid creation of bispecific antibodies that stimulate CD28 in the presence of tumor cells. The company is also conducting a Phase 1 study of XmAb808, a bispecific antibody targeting B7-H3 and CD28, demonstrating strong potential for enhanced immune response against tumors. Xencor's innovative technology is designed to improve therapeutic outcomes for patients with advanced solid tumors.
Xencor, Inc. (NASDAQ:XNCR) announced the upcoming presentation of preclinical data on its XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The data aims to enhance T cell activation in solid tumors by targeting ligands that are typically absent in tumor cells. The platform focuses on noteworthy solid tumor targets such as CEACAM5, mesothelin, STEAP1, and Trop-2. This research reflects Xencor's commitment to advancing cancer therapies using its innovative XmAb technology, with an emphasis on the potential for increased efficacy in treating various solid tumors.
Xencor, Inc. (NASDAQ:XNCR) reported financial results for Q4 and full year 2022, highlighting ongoing clinical advancements and a focus on its XmAb® drug candidates. The company recorded total revenue of $21.6 million for Q4 2022, down from $154.0 million in Q4 2021, with full-year revenue at $164.6 million, down from $275.1 million. R&D expenses remained steady at $51.5 million for Q4 2022, while G&A expenses rose to $12.8 million. Xencor anticipates ending 2023 with $425 million to $475 million in cash, supporting operations through 2025. The company aims to initiate multiple Phase 1 studies for new therapies later in 2023.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
